MY177001A - Phenothiazine compounds for treating mild cognitive impairment - Google Patents

Phenothiazine compounds for treating mild cognitive impairment

Info

Publication number
MY177001A
MY177001A MYPI20095255A MYPI20095255A MY177001A MY 177001 A MY177001 A MY 177001A MY PI20095255 A MYPI20095255 A MY PI20095255A MY PI20095255 A MYPI20095255 A MY PI20095255A MY 177001 A MY177001 A MY 177001A
Authority
MY
Malaysia
Prior art keywords
cognitive impairment
mild cognitive
treating mild
phenothiazine compounds
phenothiazine
Prior art date
Application number
MYPI20095255A
Other languages
English (en)
Inventor
Claude Michel Wischik
Gernot Riedel
Dominic Venay Harbaran
Serena Deiana
Damon Jude Wischik
Roger Todd Staff
Elizabeth Anne Goatman
Alison Dorothy Murray
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MY177001A publication Critical patent/MY177001A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20095255A 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment MY177001A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
MY177001A true MY177001A (en) 2020-09-01

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20095255A MY177001A (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2013191T6 (pl) 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
MY161656A (en) * 2007-10-03 2017-04-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines
SG185094A1 (en) 2010-04-30 2012-12-28 Prostetta Antiviral Inc Antiviral compounds
PT2673266T (pt) * 2011-02-11 2016-10-07 Wista Lab Ltd Sais de fenotiazina diamínio e sua utilização
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
EP2951149B1 (en) * 2013-01-30 2018-10-10 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
WO2016133995A1 (en) * 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
FI3487505T3 (fi) 2016-07-25 2023-06-05 Wista Lab Ltd Diaminofenotiatsiinien antaminen ja annostus
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
SI3826639T1 (sl) 2018-07-26 2025-01-31 Wista Laboratories Ltd. Optimizirano odmerjanje diaminofenotiazinov v populacijah
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
CA2579169C (en) * 2004-09-23 2018-03-06 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
CN101460157B (zh) 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
PL2013191T6 (pl) 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
CN101460222B (zh) 2006-03-29 2013-12-04 维斯塔实验室有限公司 锍化合物及其用途
MY148145A (en) * 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds

Also Published As

Publication number Publication date
PL2167095T3 (pl) 2019-11-29
US20100184752A1 (en) 2010-07-22
CN101820884A (zh) 2010-09-01
JP5725605B2 (ja) 2015-05-27
CN101820884B (zh) 2013-08-28
WO2008155533A2 (en) 2008-12-24
DK2167095T3 (da) 2019-07-29
EP2167095B1 (en) 2019-05-29
EP2167095A2 (en) 2010-03-31
PT2167095T (pt) 2019-08-06
CA2690746C (en) 2018-01-02
SI2167095T1 (sl) 2019-09-30
JP2010530403A (ja) 2010-09-09
HUE045460T2 (hu) 2019-12-30
AU2008265045A1 (en) 2008-12-24
BRPI0813670A2 (pt) 2014-12-30
HRP20191513T1 (hr) 2019-11-29
US9211294B2 (en) 2015-12-15
CA2690746A1 (en) 2008-12-24
AU2008265045B2 (en) 2014-02-27
WO2008155533A3 (en) 2009-02-19
ES2739546T3 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
NL301145I1 (enExample)
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
NZ593474A (en) Compositions and methods for treatment of celiac disease
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
TW200716624A (en) Compounds for modulating TRPV3 function
TNSN08400A1 (en) Organic compounds and their uses
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
EP1924293A4 (en) COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
ZA201002764B (en) Benzodiazepinone compounds useful in the treatment of skin conditions
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2010002909A (es) Metodo de tratamiento de pacientes de hepatitis c.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY155340A (en) Use of cathepsin c
TW200716088A (en) Formulations and methods for treating amyloidosis
TW200716015A (en) Methods and apparatuses for sealing ophthalmic lens packages